Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Multiple Clostridium Difficile Strains Cause Severe Patient Outcomes

By LabMedica International staff writers
Posted on 08 Sep 2015
Clostridium difficile is the most common cause of hospital acquired infections in the USA and the incidence of C. More...
difficile infection (CDI) has increased dramatically since 2001, coinciding with the emergence of the epidemic ribotype 027 (R027).

The high mortality rate associated with R027 led to it being described as a hypervirulent strain and since that characterization, additional ribotypes of C. difficile have been described as hypervirulent using similar criteria, but the impact of C. difficile ribotype on disease outcomes remains unclear, especially in endemic rather than epidemic settings.

Scientists at the University of Houston College of Pharmacy (Houston, TX, USA) and their colleagues collected and cultured stool samples that tested positive for C. difficile toxin from patients who presented to any of seven different local hospitals from 2011 to 2013. The study included 715 patients aged 61 ± 18 years with females making up 63% of the study population.

Enzyme-linked immunoassay or a polymerase-chain reaction (PCR) detection of the tcdB gene in unformed stool was the diagnostic methodology used at all study sites during the study period. C. difficile toxin-positive stool samples were plated onto cefoxitin-cycloserine-fructose agar (CCFA) plates and incubated under strict anaerobic conditions for 48 to 72 hours. The growth of toxigenic C. difficile was confirmed using multiplex PCR to determine the presence of tcdA, tcdB, and binary toxin genes and fluorescent ribotyping was performed.

In this large multicenter study, C. difficile R027 was the most common ribotype and was associated with severe CDI presentation and severe CDI outcomes. Although R027 was independently associated with severe disease, R027 was not independently associated with severe outcomes. No single strain was more virulent than the others. The ribotype 014-020 was associated with significantly lower incidence of severe CDI and severe CDI outcomes compared with other ribotypes.

Samuel L. Aitken, PharmD, the lead author of the study, said, “Clinical severity markers of CDI, such as white blood cell count and albumin level, a protein in blood, are more important predictors of severe outcomes than any specific strain, especially in hospitals with no single predominant strain. Strain typing remains a valuable source of information for tracking emergence of different strains and may potentially influence treatment decisions, but clinical severity markers appear to be more important predictors for the determining the severity of CDI patient outcomes.” The study was published on August 20, 2015, in the journal Infection Control & Hospital Epidemiology.

Related Links:
University of Houston College of Pharmacy



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.